Fewer than 10% of people that would benefit from obesity jabs including Wegovy have access to them, states the World Health Organization as it issues its inaugural advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging increased and just access to this class of drugs.
Per forecasts, over two billion are projected to be obese by 2030 if no action is taken.
"Our latest guidelines recognises that obesity is a long-term condition that can be managed with holistic and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are major hurdles to universal access to the jabs that can assist patients in reducing significant body mass, explains the agency.
Weight-Loss Drug Shortage
Even in the current most optimistic case, the manufacturing of these medications might only reach about 100 million people – fewer than 10% of eligible patients, as stated by the WHO.
The recommendation urges nations and manufacturers to widen access, through approaches including licensing agreements.
The intellectual property rights on semaglutide – the main component of Novo Nordisk's Wegovy – is scheduled to end in several countries in 2026.
The Way Obesity Drugs Function
GLP-1 drugs replicate a biological compound to reduce digestion speed, reduce hunger and boost satiety so individuals reduce food intake.
People commonly start to lose weight after several weeks of starting on the once-weekly jabs.
Evidence indicates people may regain a significant portion within a year of halting the treatment, as their typical appetite come back.
To be carrying excess weight raises your likelihood for contracting medical conditions, like type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight impacts people in all nations and was responsible for millions of fatalities worldwide in 2024, as per the WHO.
